There were 796 press releases posted in the last 24 hours and 153,105 in the last 365 days.

Qualitative & Semi-Quantitative Insight from Key Opinion Leaders on Mirikizumab in Moderate-to-Severe UC, 2018 Study

/EIN News/ -- Dublin, Feb. 22, 2019 (GLOBE NEWSWIRE) -- The "KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC" drug pipelines has been added to's offering.

This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC.

Questions topics

  • Perception of Phase II mirikizumab induction data in UC
  • Perception of mirikizumab's Phase III study in UC
  • Future expectations of mirikizumab in UC
  • Future expectations for mirikizumab in Crohn's disease

Key Highlights

  • All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while flagging the lack of dose response
  • Endoscopic & histological healing highlighted by most KOLs as suitable secondary endpoints in mirikizumab's ongoing Phase III UC trial
  • KOLs could not differentiate the clinical profile of mirikizumab in UC from other anti-IL-23s, and were divided over its dosing regimen.


  • The insight briefing is based on Sociable Pharma's analysis of primary research with our ulcerative colitis key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs

  • 5 Europe-based & 5 N. America-based
  • Interviews performed during July 2018

KOL data is analyzed to produce

  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts

Reasons to Buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on mirikizumab in moderate-to-severe UC
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Key Topics Covered:

  1. Executive Summary
  2. Background
  3. Research Panel Composition
  4. Results & Implications
  5. Appendix

Companies Mentioned

  • Lilly
  • Takeda
  • Pfizer
  • Janssen

For more information about this drug pipelines report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Gastrointestinal Drugs 


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.